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shunt < 2mm) of the ASD in 95.8% of 48 patients in whom the ASO was implanted and 
96.1% of 26 surgical patients. Although surgical ASD closure was performed in younger 
patients (p<0.005) with slightly larger defects (p=0.02), there was no significant differ- 
ence between the 2 groups in average Qp/Qs ratio (p=0.3). There were no deaths in 
either group. Complications occurred in 10.4% of patients in whom the ASO was 
implanted, all of which were minor, and 42.3% of patients who underwent surgery, 2 of 
which were major. The mean estimated cost (in FY2000 U.S. dollars) per case treated 
with the ASO was $11,541 (+/- $2,380), as compared with $22,695 (+/- $6,250) per case 
treated surgically (p<0.005). The average length of hospital stay per case treated with 
the ASO was 1,0 day (+/-0.2), as compared with 6.2 days (+/-3.0) per case treated surgi- 
cally (p<0.005). Sensitivity analyses based on our data identified no plausible situations 
in which the costs of surgery and of implantation of the ASO would be equal. 
Conclusions: The equally effective and less costly Amplatzer septal occluder appears 
superior to surgical closure of isolated secundum atrial septal defects in qualifying 
patients. The transcatheter method is also associated with significantly less morbidity. 
Consequently, our results support the use of the Amplatzer septal occluder as an alterna- 
tive to surgery for the management of this common congenital lesion. 
1048-169 Are Minimal Elevations of Postoperative Cardiac 
Troponin I Levels Following General Surgery 
Prognoetically Important? 
Michael J. Porter, John F. Moran, David Leder, Stephan Kahn, Krystyna Malinowska, 
Loyola University Health System, Maywood, Illinois. 
Introduction: Cardiac troponin I has a high specificity for cardiac injury, because cardiac- 
specific antibodies do not cross-react with skeletal muscle isoforms of troponin I. Cardiac 
treponin I elevations >0.1 ng/ml have important prognostic value in patients with acute 
coronary syndrome. However, the significance of troponin I levels between 0.1 and 2.5 
ng/ml in patients following general surgery is unclear. 
Methods: We retrospectively reviewed medical records of 304 patients who had under- 
gone abdominal, orthopedic, and other general surgical procedures in our institution 
between 7/99 and 6/00. Patients with clinical evidence of acute coronary syndrome or 
myocardial infarction were excluded from the study. We identified 167 patients with a 
measurable post-operative (OP) peak troponin level between 0.1 and 2.5 ng/ml. The car- 
diac troponin I levels were obtained with a chemiluminescent echnique on the Bayer 
ACS Centaur immunoassay analyzer (Bayer Corp., East Walpole, MA). Troponin I levels 
suggested a non-linear tendency, so log transform of troponin I levels was used to ana- 
lyze data by Pearson's correlation, the Student-t test, and ANOVA. 
Results: Out of 167 patients, 48% were men and 52% were women with mean age of 
72.9-J:13.1 (range 26 to 99) years, 33.5% were on ~-blockers, and 70.1% had abnormal 
post-OP electrocardiograms, with a mean follow-up of 303.5+~39.3 (range 0 to 737) 
days. There were significantly more complications at one month, two months and three 
months post-OP with more elevated troponin I levels t=21.2, p<0.001; t=22.0, p<0.001 
and t=18.5, p<0.001, respectively. Complications during the first three post-OP months 
included 4 acute myocardial infarctions, 8 cases of congestive heart failure, and 19 
deaths. Most of the troponin I elevations occurred in older patients, in patients not treated 
with pre-OP ~-blockers (t=21.8, p<0.001), in patients with abnormal post-OP electrocar- 
diograms (t=31.3, p<0.001), and especially in men (t=22.7, p<0.001 ). 
Conclusions: Minor elevations in cardiac troponin I levels in patients undergoing general 
surgical procedures strongly affect the post-OP outcome, especially during the first three 
months. 
1048-170 Cost of Abdominal Aortic Aneurysm Repair In Canada 
and the United States 
Anva C. Brox. Adk Azoulay, Kris Filion, Mark J. Eisenberg, Jewish General Hospital, 
Montreal, Quebec, Canada. 
Background: Many studies have compared health care costs in Canada and the United 
States (U.S.) on a macroeconomic level. However, little is known about the costs of spe- 
cific procedures. We therefore performed a microeconomic omparison of costs in 
abdominal aortic aneurysm (AAA) repair among Canadian and American patients. 
Methods: We compared the costs of treating 1,077 consecutive AAA repair patients 
(556 Canadian and 521 American) from 4 Canadian and 6 U.S. hospitals between 1997 
and 2001. All participating hospitals used the same cost accounting system to provide 
per-patient demographic, clinical, and cost data (excluding physician's fees), Canadian 
dollar costs were converted to U.S. dollar costs using purchasing power parities. 
Results: The mean age of AAA repair patients was similar in Canadian and American 
hospitals (69.9 ± 11.3 vs. 71.1 _+ 15.0years, p=ns) as was sex distribution (79.1% vs. 
76.0%, p=ns). The mortality rate in Canada was 12.1% vs, 10.0% (p=ns). Cost for AAA 
repair differed between Canadian and American hospitals. The median cost for AAA 
repair was $9,407 (mean $15,866 ± $18,631) in Canada as opposed to $13,802 (mean 
$24,582 ± $37,001) in the U.S. (p<0.0001). Direct costs accounted for 56.8% of total 
costs in the U.S. versus 67.1% in Canada. 
Conclusion: There is an approximate twofold difference in cost of AAA repair between 
the U.S. and Canada. Both direct and indirect costs are lower in Canada but direct costs 
make up a higher percentage of total cost than they de in the U.S. This cost discrepancy 
cannot be explained by differences in patient demographics or rates of in-hospital com- 
pUcations. 
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1073-163 Predictors of Hospital Outcome After First 
Percutaneous Coronary Intervention in the Community 
Audrey H. Wu, J. Richard Goss, Charles Maynard, Douglas K. Stewart, Xue-Qiao Zhao, 
University of Washington, Seattle. 
Background: Previous studies of hospital outcomes after first percutaneous coronary 
intervention (PCI) were performed prior to significant advances in PCI practice, or were 
performed in a retrospective or controlled manner. We examined the combined outcome 
of post-procedural myocardial infarction (MI) or in-hospital death after first PCI in a pro- 
spective manner, as currently practiced in the community. Methods: The Clinical Out- 
comes Assessment Program is a prospective, ongoing ststewide database that includes 
consecutive patients undergoing isolated PCI in Washington state (19 sites). Data from 
1/1/99 to 1/1/00 were obtained from COAP. Multivariate logistic regression modeling was 
used to determine risk of the combined outcome. Results: A total of 17,193 cases of first 
PCI were identified, including 11,399 (67.4%) males, with an average age of 63.9 + 12.2 
years. 3737 (21.9%) subjects had diabetes, 9946 (58.8%) had hypertension, and 2859 
(16.7%) had prior coronary bypass surgery. Significant predictors of the combined out- 
come include older age (20 year increments; adjusted OR 1.31; 95% CI 1.07, 1.60), 
shock (adjusted OR 2.73; 95% CI 1.70, 4.38), and more urgent priority vs. elective status 
(urgent - adjusted OR 1.74; 95% CI 1.18, 2.56; emergent - adjusted OR 5.95; 95% CI 
4.10, 8.65; salvage - adjusted OR 29.46; 95% CI 10.80, 80.31). PCI by slant vs. angio- 
plasty predicted lower incidence of the combined outcome (adjusted OR 0.69; 95% CI 
0.51, 0.93). Gender, history of diabetes, and treatment with glycoprotein (GP) Mb/llla 
inhibitors were not significantly associated with risk for the combined endpoint. Conclu- 
sion: Similar to previously published findings from retrospective series and clinical trials, 
several factors - including older age, shock, and more urgent priority - were associated 
with increased risk of post-procedural MI or in-hospital death among patients undergoing 
first PCI in the community. The lack of benefit seen with treatment with GP lib/Ilia inhibi- 
tors in the combined in-hospital endpoint may not necessarily contradict published find- 
ings, which primarily report improved intermediate-term Outcomes. 
1073-164 Predictors of Repeat Percutaneous Coronary 
Intervention Within One Year After First Percutaneous 
Coronary Intervention 
Audrey H. Wu. J. Richard Goss, Charles Maynard, Douglas K. Stewart, Xue-Qiao Zhao, 
University of Washington, Seattle. 
Background: Prior studies of repeat revasculadzation after first percutaneous coronary 
intervention (PCI) were performed in a retrospective or controlled manner, and were per- 
formed prior to recent advances in PCI practice. We determined the risk factors for 
revascularization by repeat PCI after first PCI in a prospective manner, as currently prac- 
ticed in the community. Methods: The Clinical Outcomes Assessment Program is a pro- 
spective, ongoing database that includes consecutive patients undergoing PCI in 
Washington state (19 sites). Data from 1/1/99 to 1/1/00 were analyzed. Repeat PCI was 
defined as a second PCI performed in the same coronary vessel territory 2-12 months 
after a first PCI. Multivariate logistic regression modeling was used to determine risk of 
repeat PCI. Results: 17,t93 cases of first PCI were identified, including 11,399 (67.4%) 
males, with an average age of 63.9 ± 12.2 years. 3737 (21.9%) subjects had diabetes 
and 2859 (16.7%) had prior coronary bypass surgery (CABG). 12,619 (82.6%) PCI pro- 
cedures were stents. Glycoprotein lib/Ilia inhibitors (GP2B3AI) were used in 11,569 
(67.9%) first PCI procedures. There were 924 cases of second PCI performed in any cor- 
onary vessel territory. Of these, 373 (40.4%) were repeat PCI. Prior CABG (adjusted OR 
1.59; 95% CI 1.18, 2.15) and chronic obstructive pulmonary disease (COPD) (adjusted 
OR 1.67; 95% CI 1.13, 2.48) significantly predicted repeat PCI. Lower incidence of 
repeat PCI was significantly associated with emergent vs. elective priodty (adjusted OR 
0.55; 95% CI 0.35, 0.88), use of GP2B3AI (adjusted OR 0.63; 95% CI 0.48, 0.81), and 
older age (20 year increments; adjusted OR 0.70; 95% CI 0.57, 0.86). History of diabetes 
was not significantly associated with risk of repeat PCI. Conclusion: in current commu- 
nity practice, treatment with GP2B3AI at the time of first PCI is one of the strongest pre- 
dictors of freedom from repeat PCI in the same coronary vessel distribution up to one 
year afterwards. Our data did not include repeat revascularization by CABG, which may 
explain why older age predicted a lower incidence, COPD predicted a higher incidence, 
and diabetes was not significantly associated with repeat PCI. 
1073-165 Low Body Mass Index Is an Important Correlate of Fatal 
and Nonfatal Complications After Percutaneous 
Coronary Interventions 
Maure Moscucci, Anthony C. DeFranco, David Share, Michael O'Dormell, William L. 
Meengs, Ann MaxwelI-Eward, John G. McGinnity, Kirit Patel, Vivian L. Clark, Dean E. 
Smith, Eva Kline-Rogers, Kim A. Eagle, For The Blue Cross Blue Shield of Michigan 
Cardiovascular Consortium (BMC2), University of Michigan, Ann Arbor, Michigan. 
Body Mass index (BMI) has been found to be a risk factor for complications following cor- 
onary artery bypass surgery (CABG). There are currently no data on the relationship 
between BMI and complications following percutaneous coronary interventions (PCI). 
Thus, we evaluated the relationship between BMI and in-hospital outcomes of patients 
